A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2018
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of intravenous (IV) CR845 at a dose of 0.5 mcg/kg administered after each dialysis session. The study includes a 12-week Double-blind Phase and a 52-week Open-label Extension Phase.
Epistemonikos ID: 344876e61292313b3d1163de82a0c0b280240cc2
First added on: Dec 20, 2022